The Aspirin Foundation Scientific Conference: the history, the present state and the future of aspirin prophylaxis.
Smith T., Elwood P., Keating C., Rothwell P., Detering E., Freedman A., Langley R., Logan R., Phillips C., DeCensi A.
The 2013 Aspirin Foundation Conference covered a range of topics from clinical and medical history, epidemiology, health economics, and the current uses of aspirin in general practice and in the treatment and prevention of cancer. The use of aspirin as primary prevention in people at risk of atherosclerotic events is now well known, but its use as a preventative agent in some cancer types is still under discussion, and data on colorectal and lung cancer were presented at this meeting. The potential use of aspirin in preventing vascular disease in HIV patients was also discussed. The cost effectiveness of aspirin as a primary prevention strategy was discussed for the first time in this series of meetings.